Legality & Compliance
Our commitment to transparency about the regulatory landscape for compounded peptides, IRB-approved research, and practitioner protections.
Peptide Pure Research Network (PPRN) operates at the intersection of cutting-edge regenerative medicine and an evolving regulatory landscape. We believe you deserve complete transparency about what that means, including the grey areas.
This page lays out the legal frameworks and regulatory realities practitioners should understand before working with peptides. It is not legal advice. It also will not explain why glutathione is an endogenous tripeptide available over-the-counter while KPV is not. What it will do is name the grey areas instead of stepping around them. A practitioner who understands the terrain protects their patients and their license better than one who does not. AI will continue to expand health sovereignty, not contract it. Moving ahead through this uncertainty rewards the disciplined. Our goal: integrity, quality, and full transparency.
IMPORTANT DISCLOSURE
This page is for informational and educational purposes only. It does not constitute legal advice. If you have legal questions about your practice's regulatory exposure, consult a healthcare attorney.
Sourcing Standards & Regulatory Frameworks
Peptide Pure sources through multiple qualified channels, each operating under specific federal regulatory frameworks:
Peptide therapies prescribed through PPRN-affiliated practitioners are sourced from licensed compounding pharmacies operating under Section 503A or Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
- 503A pharmacies compound medications pursuant to valid, patient-specific prescriptions from licensed practitioners.
- 503B outsourcing facilities operate under direct FDA oversight and may distribute compounded medications without patient-specific prescriptions.
- DMF-registered API suppliers provide bulk active pharmaceutical ingredients with Drug Master File documentation on record with the FDA, the same regulatory framework relied upon by mainstream pharmaceutical manufacturers.
- cGMP-compliant facilities operate under Current Good Manufacturing Practice standards. ISO 9001 certification documents adherence to international quality management standards.
- Peptides supplied through Peptide Pure carry Certificates of Analysis with multi-lab verification.
Compounding pharmacies may not compound drugs that are "essentially a copy" of a commercially available FDA-approved product unless that product appears on the FDA Drug Shortage List at the time of compounding, distribution, and dispensing.
IRB-Approved Research Protocol
All peptide therapies administered through PPRN are conducted under an Institutional Review Board (IRB)-approved research protocol:
Protocol
PPRN-001-2025
IRB Approval
IRCM-2025-467
Principal Investigator
M. Scott Mortensen, MD, MPAS, PA-C
IRB oversight provides an additional layer of patient protection, requiring informed consent, adverse event reporting, data integrity standards, and periodic review of outcomes. This is the same framework used by academic medical centers conducting clinical research.
21 CFR Part 11 & HIPAA Compliance
PPRN data collection systems are designed for compliance with 21 CFR Part 11 (electronic records and signatures) and HIPAA privacy and security rules. Patient data is encrypted, access-controlled, and auditable.
The Grey Area: What You Need to Know
GLP-1 Receptor Agonists (Sema & Tirz)
This is the most legally contentious area in compounding pharmacy today.
The FDA removed tirzepatide from the Drug Shortage List in October 2024 and semaglutide in February 2025. Once a drug is off the shortage list, compounding pharmacies lose their legal basis to compound "essentially a copy" of the branded product.
CEASE-AND-DESIST RISK
Novo Nordisk (Ozempic/Wegovy) has filed over 130 lawsuits across 40+ states against compounding pharmacies and telehealth companies. As of February 2026, Novo escalated with a sweeping patent infringement suit against Hims & Hers.
Eli Lilly (Mounjaro/Zepbound) has filed dozens of similar lawsuits and cease-and-desist campaigns targeting clinics, compounding pharmacies, and medical spas.
Both companies are sending hundreds of cease-and-desist letters demanding immediate cessation of compounding activities, with recipients given days to respond or face civil litigation and regulatory referral.
Some compounding pharmacies and legal advocates are fighting back. The Outsourcing Facilities Association filed suit against the FDA in February 2025, challenging the semaglutide shortage resolution. Some pharmacies are reformulating with different salt forms (e.g., semaglutide sodium vs. semaglutide acetate) to argue their products are not "essentially a copy." Courts are still deciding these questions.
PPRN POSITION
PPRN does not take a position on whether compounded GLP-1s will remain legally available long-term. We do take the position that practitioners should enter this space with eyes open.
Non-GLP-1 Peptides (BPC-157, CJC-1295, Thymosin, etc.)
The FDA maintains a categorization system for bulk drug substances used in compounding:
- Category 1: Eligible for compounding. FDA will not take enforcement action.
- Category 2: FDA has historically flagged for review pending further evaluation. Recent status changes are expected to be formalized through the FDA's compounding advisory process.
- Category 3: Under evaluation. Status pending.
12 peptides removed from Category 2 effective April 22, 2026: BPC-157, LL-37 (Cathelicidin), DiHexa, DSIP (Emideltide), Epitalon, GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, TB-500. *Removal from Category 2 does not equal placement on the 503A bulks list.
PPRN SOURCING POLICY
Peptides made available through Peptide Pure are sourced through multiple qualified channels depending on intended use. These include FDA-registered 503A and 503B compounding pharmacy partners, DMF-registered API suppliers, cGMP-compliant facilities, and ISO 9001-certified manufacturers. Every batch carries a Certificate of Analysis with multi-lab verification confirming greater than 99% purity. What a licensed practitioner does with a peptide once it is in their possession, is the practitioner's clinical and legal responsibility.
Legal Structures & Protections
Non-Profit Research Organization (501(c)(3))
Peptide Pure Research Network operates in collaboration with Mortensen Medical, a 501(c)(3) non-profit research organization. This structure:
- Separates research activities from commercial interests
- Provides institutional backing for IRB-approved protocols
- Ensures that patient safety and scientific integrity, not profit, drive treatment decisions
- Aligns with FDA expectations for legitimate clinical research
Private Membership Association (PMA)
As an alternative or supplemental legal framework, some practitioners in the peptide and regenerative medicine space operate under a Private Membership Association (PMA) structure.
A PMA is grounded in the First and Fourteenth Amendment right to free association, as affirmed in Griswold v. Connecticut (1965) and subsequent Supreme Court decisions. Within a PMA:
- Members voluntarily join a private association and consent to receive services outside the scope of public regulatory frameworks.
- The association operates as a private contract between consenting adults, not a public-facing commercial entity.
- Services provided within the association may not be subject to the same licensing and regulatory requirements as publicly offered medical services.
PRACTITIONER GUIDANCE
PPRN recommends that practitioners who wish to explore a PMA structure consult a healthcare attorney with specific experience in private association law and FDA enforcement. For more information on a PMA: Ken Mason, Certified: Advanced Legal Researcher PMA Solutions / MEI Strategies Email: meistrategies@gmail.com Cell: 940.453.1741
How PPRN Protects Practitioners
Participating in PPRN provides practitioners with multiple layers of legal and professional protection:
- IRB-Approved Protocol: Demonstrates that treatments are part of a legitimate, supervised research framework — not ad hoc prescribing.
- Informed Consent Templates: Standardized, IRB-reviewed consent forms that document patient understanding of risks, benefits, and the investigational nature of therapies.
- Adverse Event Reporting: Structured AE reporting to the IRB within 24 hours for SAEs, demonstrating active safety monitoring.
- Data Capture Standards: 21 CFR Part 11-aligned data collection showing scientific rigor, not just commercial distribution.
The Bottom Line
Peptide therapy exists in a regulatory grey area. We are honest about that because we believe trust is built through transparency, not through making claims that are too good to be true.
What we can tell you:
- Every treatment is conducted under an IRB-approved research protocol with proper informed consent.
- Every adverse event is reported and tracked.
- Our goal is to generate the clinical evidence that will either validate these therapies for mainstream adoption or identify risks that justify restricting them.
What we cannot tell you:
- That compounded GLP-1 agonists will remain legally available in their current form. The legal landscape is shifting rapidly.
- That a PMA structure will definitively protect you from FDA enforcement. It may help, but it has not been battle-tested for this specific use case.
- That peptide therapy is "FDA-approved." Some peptides are. Others are not. It is investigational, and participants should understand that clearly.
If you have legal questions about your practice's exposure, we encourage you to consult a healthcare attorney. PPRN is a research network, not a law firm.
Questions?
Contact Our Team
Reach out with any questions about our research protocols, regulatory framework, or practitioner enrollment.
Last updated: April 2026